Evidence map›Paper›PMID 41810351›Full record

ReviewWorld journal of clinical oncology2026

Lipid metabolism in pancreatic cancer treatment.

Chi Zhang, Hao Wang, Yan-Hui Yang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chi ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.
Hao WangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.
Yan-Hui YangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, Henan Province, China. yangyanhui63@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC) represents one of the most formidable challenges in oncology, necessitating continuous innovation in therapeutic strategies. Owing to its pivotal role in PC progression, lipid metabolism, which is characterized by dysregulated cholesterol biosynthesis, altered fatty acid profiles, and lipid-driven immunosuppression, has received increasing attention. These metabolic aberrations fuel tumour growth, chemoresistance, and metastasis while impairing immune surveillance. By targeting lipid pathways, emerging therapies hold promise for disrupting cancer cell survival and redefining PC treatment paradigms.

Indexed as

Cancer therapyDrug resistanceImmune suppressionLipid metabolismPancreatic cancer

Identifiers

PMID41810351
PMCPMC12968557

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.